Downregulating TOX expression improves the anti-tumor function of CD8+ T cells, which can synergize with immune checkpoint suppression by anti-PD1, providing a promising strategy to enhance cancer immunotherapy (17). The gene discussed is CD8A; the disease is neoplasm.